Pricing Log in Create free account

Kalaris Therapeutics Inc. (KLRS) vs LeonaBio, Inc. (LONA)

Kalaris Therapeutics Inc. and LeonaBio, Inc. are both Biotechnology companies. Kalaris Therapeutics Inc. and LeonaBio, Inc. are of similar size ($49.8M and $47.8M). Across the 8 metrics below, Kalaris Therapeutics Inc. leads on 6 and LeonaBio, Inc. on 2.

Valuation

Metric KLRS LONA Biotechnology median
P/E n/m n/m 8.50
P/S n/m n/m 9.71
P/B 0.83 3.67 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.55 n/m 0.64
EV/Sales n/m n/m 9.21
Earnings yield (101.00%) (444.41%) (33.15%)
Free cash flow yield (85.89%) (50.22%) (25.50%)

Profitability

Metric KLRS LONA Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (79.91%) (431.39%) (56.36%)
Return on assets (46.02%) (306.05%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric KLRS LONA Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) 94.50% 1.98% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KLRS LONA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 10.98 7.01 4.72
Net debt to EBITDA 2.54 0.87 0.96

Dividend

Metric KLRS LONA Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric KLRS LONA Biotechnology median
Market cap 47.83m 49.84m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack